

UPDATE REGARDING BRISTOL MYERS SQUIBB 340B PRACTICE

This notice describes updates to BMS's 340B practice that is applicable to all 340B covered entity types. These updates reflect the inclusion of standard business practices that support 340B program integrity and help ensure lawful purchasing pursuant to BMS's offer to eligible covered entities to purchase covered outpatient drugs for their eligible patients.

Questions regarding these 340B practice updates may be submitted to BMS340B@bms.com.

What is changing?

Claim Data Element Requirements for certain covered outpatient drugs:

Beginning on May 1, 2026, all covered entities will now be required to submit claim-level data (CLD) elements for all 340B utilization for certain covered outpatient drugs, as listed in Table 1. This includes utilization for all dispenses and administrations from both entity-owned pharmacies and any eligible, designated contract pharmacies. CLD information must be submitted within 45 days of the date of dispense/date of service.

BMS will continue to utilize the 340B ESP platform as the only method to collect the claims for the products included in this change.

What is not changing? (BMS's practice regarding 340B contract pharmacies as described below remains unchanged)

BMS will recognize up to five designated 340B contract pharmacy locations for each 340B covered entity that does not have its own entity-owned pharmacy (as described in the FAQs below): effective July 1, 2024, one for certain covered outpatient drugs (non-IMiDs), a second for our immunomodulatory drugs (IMiDs) (Revlimid[®], Pomalyst[®], and Thalomid[®]), and a third for Camzyos[®]; effective October 1, 2024, a fourth for Krazati[®]; and, effective July 1, 2025, a fifth for Augtyro[™]. BMS will continue to offer 340B prices on drugs sold to eligible covered entities and delivered to their entity-owned pharmacies, in compliance with applicable law. To ensure transparency and program integrity at designated contract pharmacies, BMS expects that all dispensing to 340B-eligible patients will occur at the properly designated contract pharmacy location(s), and that 340B

drugs will be shipped directly to that location either by BMS or an authorized distributor.

Contract Pharmacy Designations. Covered entities must make contract pharmacy designations at least 15 calendar days in advance of the date of their first purchase under this practice. Contract pharmacy designations may be made by visiting <https://www.340besp.com/designations>.

Non-IMiDs. BMS will permit each covered entity that lacks its own entity-owned pharmacy to select and utilize a single designated contract pharmacy location for non-IMiD products. The non-IMiD contract pharmacy location selected by the covered entity need not be the same pharmacy as the IMiD, Camzyos[®], Krazati[®] or Augtyro[™] contract pharmacy location, although it may be. Entities that choose to access non-IMiDs at 340B prices at a non-IMiD-designated contract pharmacy location will submit claim information to BMS, via 340B ESP[™] platform, subject to the applicable BMS Terms of Use. Only one 340B purchase may occur on a single eligible non-IMiD prescription. Only one covered entity may claim the 340B discount on a given dispense.

IMiDs. 340B covered entities that are not already part of the IMiD limited distribution network will have the option to access the IMiDs at 340B prices through one in-network IMiD-designated specialty contract dispensing pharmacy location per applicable covered entity. This update does not amend or expand the IMiD limited distribution network of pharmacies and will not affect access to the IMiDs for any patient. Patients receiving IMiDs will still be able to receive their medications from the same dispensaries. Entities that choose to access IMiDs at 340B prices at an IMiD-designated specialty contract pharmacy location **will continue to submit claim information to BMS directly**, subject to the applicable BMS Terms of Use. Only one 340B purchase may occur on a single eligible IMiD prescription. Only one covered entity may claim the 340B discount on a given dispense.

Camzyos[®]. 340B covered entities that are not already part of the Camzyos[®] limited distribution network will have the option to access Camzyos[®] at 340B prices through one in-network Camzyos[®]-designated specialty contract dispensing pharmacy location per applicable covered entity. Entities that choose to access Camzyos[®] at 340B prices at a Camzyos[®]-designated contract pharmacy location will submit claim information to BMS, via 340B ESP[™] platform, subject to the applicable BMS Terms of Use. Only one 340B purchase

may occur on a single eligible Camzyos® prescription. Only one covered entity may claim the 340B discount on a given dispense.

Krazati®. 340B covered entities that are not already part of the Krazati® specialty distribution network will have the option to access Krazati® at 340B prices through one in-network Krazati®-designated specialty contract dispensing pharmacy location per applicable covered entity. Entities that choose to access Krazati® at 340B prices at a Krazati®-designated contract pharmacy location will submit claim information to BMS, via 340B ESP™ platform, subject to the applicable BMS Terms of Use. Only one covered entity may claim the 340B discount on a given dispense.

Augtyro™. 340B covered entities that are not already part of the Augtyro™ specialty distribution network will have the option to access Augtyro™ at 340B prices through one in-network Augtyro™-designated specialty contract dispensing pharmacy location per applicable covered entity. Entities that choose to access Augtyro™ at 340B prices at an Augtyro™-designated contract pharmacy location will submit claim information to BMS, via 340B ESP™ platform, subject to the applicable BMS Terms of Use. Only one covered entity may claim the 340B discount on a given dispense.

BMS remains committed to working with covered entities to protect the integrity of the 340B program and to help ensure that uninsured and low-income patients can access the medications they need at the 340B price. BMS will continue to apply its practice as circumstances require to fulfill applicable legal obligations and support practice requirement.

Questions regarding these 340B practice updates may be submitted to BMS340B@bms.com.

Table 1

List of Certain Birstol Myers Squibb Products that Require Claim Data Elements

Abraxane[®]	Evotax[®]	Onureg[®]	Reyataz[®]
Azactam[®]	Idhifa[®]	OPDIVO[®]	Sotyktu[®]
Baraclude[®]	Inrebic[®]	Opdivo Qvantig[™]	Sprycel[®]
Cobenfy[™]	Istodax[®]	Opdualag[™]	Vidaza[®]
Eliquis[®]	Kenalog[®]	Orencia[®]	Yervoy[®]
Empliciti[®]	Nulojix[®]	Reblozyl[®]	Zeposia[®]